Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.
about
The role of epigenetics in kidney malignanciesTrials with 'epigenetic' drugs: an updateThe role of DNA methylation in aging, rejuvenation, and age-related diseaseEpigenetic modulators as therapeutic targets in prostate cancerEpigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesAberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progressionTargeting DNA methylation for epigenetic therapy.Use of epigenetic drugs in disease: an overview.Expression profiling and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in sporadic human renal cell carcinoma.The emerging nexus of active DNA demethylation and mitochondrial oxidative metabolism in post-mitotic neuronsDNA demethylating antineoplastic strategies: a comparative point of viewMutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapyReprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.Kinetics of DNA methylation inheritance by the Dnmt1-including complexes during the cell cycle.Epigenetics of kidney cancer and bladder cancer.Targeting the epigenome: effects of epigenetic treatment strategies on genomic stability in healthy human cellsEpigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy.DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cellsChromatin, cancer and drug therapies.Modulation of DNA methylation by a sesquiterpene lactone parthenolide.Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.Manipulating the epigenome for the treatment of urological malignancies.Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy.Epigenetic therapy in urologic cancers: an update on clinical trials.DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.The application of delivery systems for DNA methyltransferase inhibitors.Epigenetic drug discovery: targeting DNA methyltransferases.Epigenetic targets in human neoplasms.Promises and challenges of anticancer drugs that target the epigenome.Epigenetic-based therapies in cancer: progress to date.Quantum rods as nanocarriers of gene therapy.Clinical pharmacokinetics of second generation antisense oligonucleotides.Nucleic acid drugs in the clinic.Management of metastatic kidney cancer in the era of personalized medicine.Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers.Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view.DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.Rewiring the solid tumor epigenome for cancer therapy.Effects of DNA methyltransferase 1 inhibition on esophageal squamous cell carcinoma.New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.
P2860
Q26801233-4F9F38F0-67A5-4421-B01D-0B86A4F71FF3Q27000542-14EA9ACF-09AD-4208-85EF-33D2B797CEBAQ27025194-B7349C6B-CF7A-491A-A810-0FFBBC1D19ADQ28071912-5CB1D9BB-5BA8-490D-A16A-000BE2556E8DQ33980682-1644FE69-2202-4EE9-87DF-635FB44DFAD9Q34130236-DE65AB23-BECC-4FC3-8305-1603779B33EAQ34258037-08676351-870C-449B-AF91-38545F39B661Q34607095-AD9CDDFE-9284-481E-9BC4-5B642331C1F6Q34733206-C706C57E-0E91-4B69-9DD4-4EB09652BAEEQ34834731-11CB8C47-16BB-443A-8B8F-24C92D7F2615Q34972245-7136F19C-30C8-4BD1-BFD5-83AB8B3F02BEQ35132953-95829E8D-8561-4343-8938-724F933A7AE1Q35563726-F52A4A7A-3CC5-480E-A57D-962DECE9FC7FQ35839338-EFF85870-E083-4C10-8DC4-591C8B6139EFQ35857807-8A48DAB6-D980-419C-B5B5-0BF51995218BQ36001852-E5CDA43B-ABA6-4B16-BDDD-2D2A386E9F1DQ36663928-66B858EB-44D0-45F7-8F79-F1345C44710CQ37016577-79FDD447-5048-4C0C-97F2-7CE5077FC0DDQ37073231-4EC0E5C5-93A2-4750-9956-9A9C9B3AF27CQ37168514-14BCA222-DDB2-40D5-8897-7CBB04AE3457Q37184917-73600857-E59D-46B7-A008-9E7E63986AE4Q37524412-82076E1F-3E80-41DD-8046-DF0C86C14568Q37575815-F99B0601-19E9-4829-8D18-BE1C026D7AC4Q37707110-6A06DBA3-2D47-4EE8-9A27-DCA3BB22C1CFQ37729405-8B7C00F6-F36B-4867-BC01-22C97816F280Q37911496-6C5A7C2A-1B81-4677-B488-D91ECADC6FC3Q37941536-0A4F5D95-A91C-423C-8F3A-8F2C14CF99D0Q37961723-AC97576D-533A-429E-8BA8-F5794D3490F0Q37962596-4F18355A-38A1-4F45-AE36-40D9D7DF4054Q37964702-BF21DD06-0EC0-4C86-B354-C3DDD1D72F38Q38014158-F9AC69E1-7ABD-44AC-A3B1-247437528810Q38066620-39339B4D-10C8-442B-AEFC-C11C3ED433B5Q38088755-596DD6F8-0652-4E66-943D-AE7AE2D76EDEQ38180744-6D58CDF9-1BDD-4F4D-9346-2BA32EA230FAQ38630962-3EF9934F-B614-4FDC-A6EF-04374781969DQ38682574-88FC5EB5-43B3-4056-A132-CDCB71D7CB77Q38833395-83E52EE5-6AB1-4887-8B85-6A0F47F97568Q38895216-F5B3D11B-2BD4-4317-A15C-9E58680960A6Q39549011-B1D91F7E-3EF1-4400-B533-C7A4B1B40140Q42153007-D99F15EC-63AB-4C1C-9486-4A7F2B724159
P2860
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Phase II trial of DNA methyltr ...... nvestigational new drug study.
@en
type
label
Phase II trial of DNA methyltr ...... nvestigational new drug study.
@en
prefLabel
Phase II trial of DNA methyltr ...... nvestigational new drug study.
@en
P2093
P921
P1476
Phase II trial of DNA methyltr ...... nvestigational new drug study.
@en
P2093
Elizabeth Eisenhauer
Eric Winquist
Gregory K Reid
Jean-Pierre Ayoub
Jennifer Knox
Laura Pearce
Nancy Wainman
P2888
P304
P356
10.1007/S10637-006-5938-1
P577
2006-03-01T00:00:00Z
P6179
1050633695